CORESTEMCHEMON, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 378
- Market Cap
- -
- Website
- http://www.corestem.com
Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Corestemchemon, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06676423
- Locations
- 🇰🇷
Hanyang university hospital, Seoul, Korea, Republic of
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Corestemchemon, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT04745299
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Pusan National University Yangsan Hospital, Yangsan, Kyungsangnam-do, Korea, Republic of
Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis
Completed
- Conditions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Corestemchemon, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04522505
- Locations
- 🇰🇷
Hanyang university hospital, Seoul, Korea, Republic of
Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)
Active, not recruiting
- Conditions
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Corestemchemon, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04495582
- Locations
- 🇰🇷
Yonsei University College of Medicine, Seoul, Korea, Republic of
Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Corestemchemon, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03265444
- Locations
- 🇰🇷
Yonsei University College of Medicine, Seoul, Korea, Republic of
Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Corestemchemon, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03174587
- Locations
- 🇰🇷
Hanyang university hospital, Seoul, Korea, Republic of
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Corestemchemon, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT01363401
- Locations
- 🇰🇷
Hanyang University Hospital, Seoul, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath